DIRS.INFO The most relevant business & tech news

☆ Need to see more fear in markets before attacking 9-12 months of gains: Cannacord Genuity's Dwyer
▼ + stars: | 2024-01-22 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNeed to see more fear in markets before attacking 9-12 months of gains: Cannacord Genuity's DwyerTony Dwyer, Canaccord Genuity chief market strategist, joins 'Squawk on the Street' to discuss what Dwyer makes of the last push on the S&P 500, Dwyer's hesitance to make a bold call for the Federal Reserve, and more.

Persons: Cannacord Genuity's Dwyer Tony Dwyer, Canaccord, Dwyer, Dwyer's hesitance Organizations: Federal Reserve

☆ How to play the next stage of AI in 2024, according to Canaccord Genuity
▼ + stars: | 2024-01-12 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

Canaccord Genuity is laying out some names poised to capitalize on the new stage of AI set to unfold in 2024. "As we enter 2024, we anticipate a marked shift from businesses creating AI strategies towards executing them, with a focus on measuring and delivering ROI." Here are some of the companies across sectors best situated to take advantage of the next stage of AI growth: Canccord Genuity sees a plethora of opportunities in the technology space beyond the pure play behemoths that prospered in 2024. "In the software security section of the report, we address how our coverage companies are implementing and/or enhancing AI strategies." But technology isn't the only industry poised to benefit from AI tailwinds this year and beyond.

Persons: Susan Anderson, Anderson, Genuity, — CNBC's Michael Bloom Organizations: Microsoft, Nvidia, Nasdaq, Deere

☆ Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
▼ + stars: | 2023-12-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. "We expect this environment to continue but look forward to the prospect of lower interest rates in 2024." When that happens, Canaccord Genuity said to expect a "strong rally across the biotech sector rewarding innovative, but riskier assets." Analysts have said the rich price reflects the opportunity for ImmunoGen's Elahere cancer treatment , which has quickly established itself as the standard of care for types of ovarian cancer. 'Oversold and cheap' In a research note Friday, Jefferies analyst Michael Yee said "a significant short squeeze" was helping biotech stocks in the fourth quarter.

Persons: Dan Lyons, Janus Henderson, John Newman, Canaccord Genuity, Janus, Lyons, Bristol Myers Squibb, Karuna, AstraZeneca, Eli Lilly, AbbVie, Jonathan Miller, Miller, bode, Jonathan Krinsky, Krinsky, BTIG's, Jefferies, Michael Yee, Yee, NASH, Madrigal, we're, David Risinger, — CNBC's Michael Bloom Organizations: Drug, Federal, Bristol Myers, Karuna Therapeutics, CART, Bristol Myers Squibb, Cerevel Therapeutics, Securities and Exchange Commission, pharma, P Biotech, Nasdaq Biotech, Apogee Therapeutics, Madrigal Pharmaceuticals, Madrigal, resmetirom, Vertex Pharmaceuticals, Leerink Partners Locations: ImmunoGen

☆ Tesla's Cybertruck is an 'awesome' yet polarizing vehicle, says Canaccord's George Gianarikas
▼ + stars: | 2023-12-01 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTesla's Cybertruck is an 'awesome' yet polarizing vehicle, says Canaccord's George GianarikasGeorge Gianarikas, Canaccord Genuity analyst, joins 'The Exchange' to discuss Tesla's new Cybertruck, the company's shares falling following the event, and more.

Persons: Canaccord's George Gianarikas George Gianarikas, Canaccord

☆ Equity prices will end the year where they currently are, says Canncord Genuity's Dwyer
▼ + stars: | 2023-11-27 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEquity prices will end the year where they currently are, says Canncord Genuity's DwyerTony Dwyer, Canaccord Genuity chief market strategist, joins 'Squawk on the Street' to discuss why investors need to 'chillax' into year-end, why prices may end the year where they currently are, and more.

Persons: Canncord Genuity's Dwyer Tony Dwyer, Canaccord

☆ Teck will be looking for metals acquisitions after the Glencore deal closes: Analyst
▼ + stars: | 2023-11-15 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTeck will be looking for metals acquisitions after the Glencore deal closes: AnalystDalton Baretto from Canaccord Genuity explains what he expects Teck to do with the proceeds of the Glencore deal, and adds there is "significant appetite" from investors for free cashflow vehicles.

Persons: Dalton Baretto, Canaccord Genuity, Teck

☆ Two chip stocks are surging this week. Options traders bet one will keep going and one will falter
▼ + stars: | 2023-11-02 | by ( Michael Khouw | ) www.cnbc.com time to read: +5 min

Two of the semiconductor stocks that reported this week saw some big post-earnings moves and substantially above-average options trading activity. Among the biggest winners were Wolfspeed Inc. (WOLF) and Advanced Micro Devices Inc. (AMD) . AMD WOLF 5D mountain AMD vs Wolfspeed, 5 days Are options markets aligned with these spikes or fading them using them as opportunities to initiate new bearish positions? Betting against Wolfspeed Wolfspeed popped sharply after a modest topline beat. Betting on AMD Unlike WOLF, AMD was up over 50% year-to-date going into the print so the pop wasn't a short-covering rally.

Persons: Wolfspeed, Roth MKM, Canaccord Genuity, Morgan Stanley Organizations: Wolfspeed Inc, Devices Inc, AMD, Carbide, JPMorgan, Citi, Deutsche Bank, WOLF, Management, Nvidia, supercomputing

☆ Odey Asset Management to close, website statement reads
▼ + stars: | 2023-10-31 | by ( Nell Mackenzie | ) www.reuters.com time to read: +2 min

Hedge fund manager Crispin Odey uses his phone outside of Hendon Magistrates' Court whilst facing one charge of indecent assault, in Hendon, London, Britain February 17, 2021. REUTERS/Toby Melville/ File Photo Acquire Licensing RightsLONDON, Oct 31 (Reuters) - Odey Asset Management, one of Britain's best known hedge funds, will shut, it said on Tuesday in a statement on its website, less than six months after its founder faced fresh allegations of misconduct. Crispin Odey, 64, was ousted in June from Odey Asset Management (OAM), which he founded in 1991, after the Financial Times and Tortoise Media reported that 13 women had alleged that he had sexually assaulted or harassed them. Where each fund manager would move, or if their fund was closed without finding an alternative home, was detailed on the hedge fund's website. No new fund manager for Sophia Whitbread, the only female portfolio manager listed, was named.

Persons: Crispin Odey, Toby Melville, Odey, James Hanbury, Jamie Grimston, Oliver Kelton, Freddie Neave, Geoffrey Marson, Canaccord Genuity, Adrian Courtenay, Green, Sophia Whitbread, Peter Martin, Nell Mackenzie, Alun John, Mark Potter Organizations: Hendon Magistrates, REUTERS, Odey, Management, Odey Asset Management, Financial Times, Tortoise Media, Asset Management, Lancaster Investment Management, Reuters, Inc, Bainbridge Partners, Thomson Locations: Hendon, Hendon , London, Britain, S.W, Mitchell

Reuters could not establish whether Canaccord's interest in the business, known as Close Brothers Asset Management, is still live. Shares in Close Brothers closed 2.2% up on Thursday after initially jumping as much as 5% on the news. Royal Bank of Canada (RY.TO) acquired London-listed Brewin Dolphin last year in an effort to bulk up its international wealth management footprint. Bloomberg first reported Close Brothers' plans to offload its wealth management division in July. Canaccord has sought to grow its UK wealth management arm via acquisitions.

Persons: Goldman Sachs, David Esfandi, OTPP, 7IM, Canaccord, Pablo Mayo Cerqueiro, Amy, Jo Crowley, Anousha Sakoui, Jane Merriman, Jonathan Oatis Organizations: Reuters, Asset Management, Royal Bank of Canada, Bloomberg, HPS Investment Partners, Thomson Locations: Toronto, London

☆ A soft landing is not going to happen, says Canaccord's Tony Dwyer
▼ + stars: | 2023-10-25 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailA soft landing is not going to happen, says Canaccord's Tony DwyerTony Dwyer, Canaccord Genuity chief market strategist, joins 'Closing Bell Overtime' to talk interest rates, what the Federal Reserve is poised to do next and the possibility of a recession.

Persons: Canaccord's Tony Dwyer Tony Dwyer, Canaccord Organizations: Federal Reserve

☆ CNBC Daily Open: Oil deals ahead of Big Tech earnings
▼ + stars: | 2023-10-24 | by ( Shreyashi Sanyal | ) www.cnbc.com time to read: +2 min

In this article GOOGL Follow your favorite stocks CREATE FREE ACCOUNTOmar Marques | Lightrocket | Getty ImagesThis report is from today's CNBC Daily Open, our new, international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Unlike more focused software companies, Microsoft "has full geographic coverage across all industry verticals," UBS analyst Karl Keirstead said, and that makes Microsoft less susceptible to downturns in any one sector or region. Most analysts predict the sales of weight loss drugs such as Wegovy and Mounjaro could easily exceed $100 billion. Still, that's conservative compared to Guggenheim's expectations of $150 billion to $200 billion in sales.

Persons: Omar Marques, Hess, Canaccord, Tony Dwyer, Karl Keirstead, Mounjaro, drugmaker Eli Lilly Organizations: Lightrocket, CNBC, Big Tech, Nasdaq, Chevron, Exxon Mobil, Stocks, Microsoft, UBS, Wall Street, Citi, Novo Nordisk Locations: .

"When the 10-year yield goes up, it will have a knock-on effect for almost everything," according to Brett House, economics professor at Columbia Business School. There are many factors driving the recent spike in Treasury yields, economists said. Most of the recent jump in Treasury yields is due to a so-called term premium, said Andrew Hunter, deputy chief U.S. economist at Capital Economics. Student loans could get pricierThere is also a correlation between Treasury yields and student loans. The government sets the annual rates on those loans once a year, based on the 10-year Treasury.

Persons: Jerome Powell, Mark Hamrick, Brett House, Andrew Hunter, Hunter, Tony Dwyer, Canaccord Genuity, Freddie Mac, Eugenio Aleman, Raymond James Organizations: Federal, Stock, Fed, Columbia Business School, Treasury, Capital Economics Locations: U.S

The world's most valuable automaker was set to lose nearly $50 billion in market value, based on premarket share movements. The comments marked a change in tone from Tesla CEO Musk, who had said his company was "recession-resilient" last year. The EV maker missed revenue estimates on Wednesday by the most in more than three years despite hefty price cuts. Reuters GraphicsOverall, 10 analysts cut their price targets on the stock, pushing the median view to $260, according to LSEG data. Tesla shares fell 6.1% at $227.96 in premarket trading.

Persons: Tyrone Siu, Elon, Tesla, Musk, Canaccord, Bernstein, Toni Sacconaghi, Craig Irwin, Aditya Soni, Akash Sriram, Shounak Dasgupta, Anil D'Silva Organizations: Tesla, REUTERS, Ford Motor, General Motors, Reuters Graphics, Ford, Roth Capital, Reuters, Thomson Locations: Taipei, Taiwan, Bengaluru

☆ Tesla tumbles as Wall St raises doubt over growth outlook
▼ + stars: | 2023-10-19 | by ( ) www.reuters.com time to read: +2 min

[1/2] The logo of Tesla is seen in Taipei, Taiwan August 11, 2017. Overall, 10 analysts cut their price targets on the stock, pushing the median view to $260, according to LSEG data. Cash crunches at small EV startups and the ongoing strike at the Detroit Three automakers have also added to the optimism around Tesla. Tesla trades at about 59 times its 12-month forward earnings estimates, compared with 6.3 times for Ford and General Motors' 4.2. Reuters GraphicsReporting by Aditya Soni and Akash Sriram in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

Persons: Tyrone Siu, Tesla, Elon Musk, Canaccord, Chaim Siegel, Elazar, Cybertruck, Cash, Aditya Soni, Akash Sriram, Shounak Dasgupta Organizations: Tesla, REUTERS, Wall Street, EV, Reuters, Elazar Advisors, Detroit Three, Ford, General Motors, Thomson Locations: Taipei, Taiwan, Bengaluru

How GLP-1 drugs work Sorting through the facts reveals some likely winners and losers. LLY YTD mountain Eli Lilly shares year to date performance It is still early days for GLP-1 medications. Many have seen the rise of GLP-1 drugs as a threat to the medical device industry. Also, not all patients are able to tolerate GLP-1 drugs, which can cause side effects such as nausea. Among other medtech stocks, Plovanic sees GLP-1 drugs as an "incremental positive" for Dexcom, which makes continuous glucose monitors (CGMs), but an "incremental negative" for insulin pump makers like Insulet.

Persons: Insulet, Medtronic, Dexcom, BAX, NASH, Eli Lilly, Peter Verdult, Lilly, Eli Lilly aren't, Piper Sandler, Wegovy, Yasmeen Rahimi, Robbie Marcus, Marcus, hasn't, Baxter, David Low doesn't, William Plovanic, Craig Wong, Pan, Plovanic, Matt O'Brien, O'Brien, Rippling, Simeon Gutman, Morgan Stanley, Gutman, — CNBC's Michael Bloom Organizations: Novo Nordisk, Baxter International, Baxter, GLP, Citi, Novo, Bank of America, Viking Therapeutics, Pharmaceuticals, Pfizer, Amgen, Companies, Fisher, Reuters, Inspire, Systems, JPMorgan, RBC Capital, Walmart, underperformance Locations: GLP, U.S, DaVita, ResMed

☆ Stocks making the biggest moves midday: Tesla, Nike, Carnival, Nvidia and more
▼ + stars: | 2023-09-29 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Tesla — Stock in the electric vehicle company added 1.5% in midday trading Friday. Canaccord Genuity reiterated a buy rating on the EV stock on Thursday ahead of vehicle deliveries data. Elsewhere, Citi remained neutral on Tesla and reduced its vehicle delivery forecast to 450,000 from 468,500. Bumble — The online dating platform added 3% after Loop Capital Markets upgraded the stock to buy from hold. Corcept Therapeutics — Shares slumped 17% in midday trading as the firm contends with ongoing litigation against Teva Pharmaceuticals.

Persons: Elon Musk, Canaccord Genuity, Tim Wentworth, Roz Brewer, Bumble —, Cushing, Teva, — CNBC's Pia Singh, Alex Harring, Michelle Fox, Hakyung Kim, Darla Mercado Organizations: U.S, Senate, Intelligence, Capitol, Washington , D.C, Citi, Barclays, Anheuser, Busch InBev — U.S, LSEG, Cruise, Wonder Group, Nvidia —, Blackwell, Nvidia, Nike —, Nike, Walgreens, Bloomberg, Therapeutics, Teva Pharmaceuticals, Texas, Northcoast Research Locations: Washington ,

☆ The market correction isn't over and won't be until these things happen, says top stock strategist
▼ + stars: | 2023-09-27 | by ( Jesse Pound | In Jesse-Pound | ) www.cnbc.com time to read: +1 min

Several technical signals suggest that the stock market is nearing oversold territory, but that doesn't mean Wall Street is poised for a true rebound, according to Canaccord Genuity strategist Tony Dwyer. The Nasdaq Composite , S & P 500 and Dow Jones Industrial Average all closed below their 50-day moving average Tuesday. Within the S & P 500, more than 85% of stocks are below their own 50-day moving average, Dwyer said in a note to clients Wednesday. But those technical signals aren't enough to confidently buy the dip, Dwyer said. The recent rise in bond yields will put a cap on any short-term rebound, according to the strategist.

Persons: Canaccord, Tony Dwyer, Dwyer, — CNBC's Michael Bloom Organizations: Nasdaq, Dow Jones Industrial, U.S . Treasury, Treasury Locations: U.S

☆ Now's the time to get ready to attack the weakness in markets, says Canacoord's Tony Dwyer
▼ + stars: | 2023-09-25 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNow's the time to get ready to attack the weakness in markets, says Canacoord's Tony DwyerTony Dwyer, Canaccord Genuity chief market strategist, joins 'Squawk Box' to discuss the latest market trends, why he believes a soft landing might be the worst case, the rest of year outlook, and more.

Persons: Canacoord's Tony Dwyer Tony Dwyer, Canaccord

☆ Stocks making the biggest moves midday: Alcoa, Nio, Williams-Sonoma, Chefs' Warehouse and more
▼ + stars: | 2023-09-25 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

Alcoa — Shares of the aluminum stock slipped 6.1% after the company said executive vice president William Oplinger would succeed Roy Harvey as CEO and president. Li Auto — U.S.-traded shares of the Chinese EV company dropped 10% following news that Huawei made moves in the increasingly competitive space. GE HealthCare Technologies — Shares of the medical technology gained 3.3%. JD.com — U.S.-listed shares of the Chinese e-commerce stock slid 2.1% as concerns over the state of the country's economy grew. Chefs' Warehouse — The specialty food distributor popped 1.6% after UBS initiated coverage of the stock at a buy.

Persons: William Oplinger, Roy Harvey, Oplinger, Nio, Li, Leonard Green, Canaccord Genuity, Yun Li, Jesse Pound, Pia Singh, Brian Evans, Hakyung Kim Organizations: Alcoa Inc, Davenport, Alcoa —, U.S, Li Auto, EV, Huawei, GE HealthCare Technologies, GE HealthCare, Williams, Sonoma —, Green Equity Investors, Partners, Dow Inc, JPMorgan, Technologies, Citi, Chefs, UBS, Hudson Technologies Locations: Riverdale , Iowa, Williams, Sonoma, —

☆ Stocks making the biggest moves midday: Ford, Scholastic, Squarespace, Deere and more
▼ + stars: | 2023-09-22 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Ford — Shares popped about 3% in midday trading after a CNBC report said both Ford and the United Auto Workers union are making headway on negotiations as the strike continues. Squarespace — The website builder popped about 5% after UBS initiated coverage of the stock at a buy. Scholastic — The publishing and media company stock plummeted more than 14% after reporting an earnings miss on the top and bottom line. Shares popped nearly 25% during its Nasdaq debut on Sept. 14 but are now trading just above the stock's $51 initial public offering price. Chinese e-commerce stocks — U.S. shares of both PDD and Alibaba added roughly 4% and 5%, respectively, while JD.com stock climbed 2.2%.

Persons: Canaccord Genuity, Alibaba, — CNBC's Pia Singh, Alex Harring, Hakyung Kim, Samantha Subin Organizations: Ford, CNBC, United Auto Workers, UBS, Scholastic, FactSet, Arm Holdings, Susquehanna, Nasdaq, Deere, Bloomberg, Activision, Microsoft

☆ Stocks making the biggest moves premarket: AstraZeneca, Wayfair, Alibaba and more
▼ + stars: | 2023-09-22 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

AstraZeneca — Shares of the British pharmaceutical company gained more than 2.7% in premarket trading after the company reported positive results for its drug Dato-DXd in a trial for treating a common type of breast cancer. Wayfair — Shares gained more than 2% after Bernstein upgraded home merchandiser to market perform from underperform. Chinese e-commerce stocks — U.S. listed shares of Alibaba and PDD Holdings added nearly 4% in premarket trading, while JD.com rose 3.3%. Arm Holdings — Shares of the chip designer added 1.3% during premarket trading. Yeti — Shares gained about 3% in the premarket.

Persons: Bernstein, Canaccord Genuity, Wells, Ralph Lauren —, Raymond James, Rick Patel, Jefferies, — CNBC's Pia Singh, Sarah Min, Samantha Subin, Tanaya Macheel, Brian Evans, Michelle Fox Organizations: AstraZeneca, AstraZeneca —, U.S, PDD Holdings, Bloomberg, Seagen, Deere, Susquehanna, Communications Locations: COVID, Smithfield, Sydney, DXd, Alibaba, China, drinkware

☆ UAW strike and Tesla: How Elon Musk could win
▼ + stars: | 2023-09-19 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailUAW strike and Tesla: How Elon Musk could winGeorge Gianarikas, analyst at Canaccord Genuity, joins 'Power Lunch' to discuss the UAW strike and how it could be a tailwind for EVs.

Persons: Elon Musk, George Gianarikas Organizations: UAW Locations: EVs

☆ Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
▼ + stars: | 2023-09-16 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Fernandez sees a total addressable market of $140 billion to support patients with obesity. He expects there is a potential for GLP-1 drugs to become as common and widely used, much like statins are used to lower cholesterol. Morgan Stanley's Flynn estimates a 30% share of the diabetes market would generate $109 billion on a worldwide basis for GLP-1 drugs. Layer in a 15% to 30% share of the obesity market and that equates to worldwide sales of $97.4 billion to $194.8 billion. Guggenheim's estimates also assume that oral GLP-1 drugs that are currently in development are able to come to market a few years from now.

Persons: Seamus Fernandez, Fernandez, Lilly, Eli Lilly, Morgan Stanley, Terence Flynn, Eli Lilly's Mounjaro, Insulet, Canaccord, William Plovanic, Plovanic, It's, Morgan Stanley's Flynn, Flynn, Novo, Michael Bloom Organizations: Wall, Novo, American Heart Association, Food and Drug Administration, Novo Nordisk, Iqvia, Disease Control Locations: GLP

☆ Here’s what major analysts thought of the new iPhone and what to do with Apple’s stock
▼ + stars: | 2023-09-13 | by ( Samantha Subin | ) www.cnbc.com time to read: +4 min

He highlighted the enhanced photo capabilities on Pro models and called the new double tap feature the most notable upgrade to the Apple Watch. Many analysts expected hikes around $100 and $200 for the beefed up Pro and Pro Max iterations. Apple essentially delivered a $100 price hike on the Pro Max by doing away with the lower storage option. He noted that the hike on the Pro Max skewed to the low end of the Wall Street firm's expectation range. Evercore ISI's Amit Daryanani regarded the event as "mildly disappointing" for bulls hoping for a Pro price increase.

Persons: Toni Sacconaghi, Canaccord Genuity's Michael Walkley, Goldman Sachs, Michael Ng, Wells, Aaron Rakers, Pro Max, iPhones, Atif Malik, Evercore ISI's Amit Daryanani, David Vogt, Samik Chatterjee, Erik Woodring's, Morgan, Apple, Woodring, Sacconaghi, — CNBC's Michael Bloom Organizations: Apple, Apple Watch, Wall, Pro, Citi, UBS Locations: China

☆ Cannabis ETFs boom as HHS recommendation to ease restrictions raises hopes for federal reform
▼ + stars: | 2023-09-12 | by ( Stefan Sykes | ) www.cnbc.com time to read: +2 min

An employee of Aurora Deutschland GmbH, a manufacturer of medical Cannabis products, inspects a flowering Cannabis plant in a greenhouse in Leuna, Germany September 11, 2023. Marijuana-related ETFs are soaring in September as investors flood back into the sector after months of waning interest. It marked a swift turnaround for a quasi-legal industry curtailed by the anemic pace of federal reform. Last month's announcement also sent shares of several cannabis companies higher, including Canopy Growth, Tilray Brands and Cronos Group. At the time of the closure announcement, fund co-founder Morgan Paxhia told CNBC that it was not "immune to the broader macroeconomic environment and, more specifically, the dramatic shift in investor sentiment that has impacted the cannabis industry."

Persons: Canaccord, Matt Bottomley, Morgan Paxhia Organizations: Aurora Deutschland GmbH, U.S . Department of Health, Human Services, Dow Jones Industrial, Dow, Tilray Brands, Cronos Group, Marijuana, CNBC Locations: Leuna, Germany

Search resuls for: "Canaccord Genuity"

25 mentions found